CytomX Therapeutics (CTMX) Interest Expenses (2014 - 2025)

CytomX Therapeutics' Interest Expenses history runs 12 years deep, the most recent figure standing at $24.6 million for Q4 2025.

• Quarterly Interest Expenses rose 969.31% year-over-year to $24.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 74.33% YoY) and the FY2025 annual result came in at $24.6 million, down 84.83% from the prior year.
• Interest Expenses was $24.6 million for Q4 2025 at CytomX Therapeutics, up from $5.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $175.5 million in Q4 2023 and bottomed at $795000.0 in Q3 2022.
• A 5-year average of $13.7 million and a median of $3.4 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 7528.43% — and 2024, when it tumbled 98.69%.
• CytomX Therapeutics' Interest Expenses stood at $1.3 million in 2021, then jumped by 75.71% to $2.3 million in 2022, then jumped by 7528.43% to $175.5 million in 2023, then tumbled by 98.69% to $2.3 million in 2024, then surged by 969.31% to $24.6 million in 2025.
• Business Quant data shows CTMX's Interest Expenses at $24.6 million in Q4 2025, $5.0 million in Q3 2025, and $5.1 million in Q2 2025.